Richard B. Moss

Results of a Phase 2a study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis and homozygous for the F508del-CFTR mutation

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Campbell PW, Bronsveld I, DeBoeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Lebecque P, McCoy KS, Moss RB, Pilewski JM, Rosenbluth D, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Thorax. 2012; 67 (1): 12-18